Mammogen Raises Up to $30M to Advance RNA Blood Test for Early Breast Cancer Detection
6 June 2026
R&D World recently featured Mammogen following the company’s Series A financing of up to $30 million to advance genTRU-breast, our RNA-powered blood test designed to support earlier breast cancer detection.
The article explores Mammogen’s approach to helping women with dense breast tissue, the ongoing pivotal study for genTRU-breast, and how additional molecular information could help guide what comes next after mammography.
The feature also includes insights from CEO Elizabeth Cormier-May and COO Marty Keiser on Mammogen’s mission, clinical strategy, and plans to bring the technology to market.
BioSpace | October 27, 2026 Mammogen has announced a clinical research partnership with MammoLink, a specialized women's health imaging provider, to expand community access to innovative breast cancer detection technologies. Through this collaboration, MammoLink will participate in Mammogen's KATELYN-ERIN clinical trial, a prospective study involving approximately 2,600 women. The partnership will leverage MammoLink's mobile 3D mammography network across Florida to evaluate Mammogen's genTRU-breast™ blood-based RNA assay alongside traditional breast imaging. The initiative represents an important step toward integrating molecular diagnostics with community-based breast care, with the goal of improving accessibility and supporting earlier breast cancer detection, particularly for women with dense breast tissue. Click Here to Read the Full Article on BioSpace
23 October 2026 America's Small Business Network (ASBN) | October 23, 2026 Mammogen CEO and Co-Founder Liz Cormier-May was featured on ASBN's The Female Founder Show, discussing the company's mission to advance breast cancer detection through innovative RNA-based blood testing. During the interview, Cormier-May highlighted the challenges women with dense breast tissue face with traditional mammography and explained how Mammogen's genTRU-breast™ blood-based assay is being developed to provide additional information that could support earlier detection. Cormier-May also shared the personal experiences behind Mammogen's founding, the challenges of advancing innovation in women's health, and her advice for aspiring female entrepreneurs. Click Here to Read the Full Article and Watch the Interview →
BioSpace | October 20, 2026 Mammogen announced the appointment of Rebecca D. Kaltman, M.D., Executive Director of the Inova Saville Cancer Screening and Prevention Center, as Principal Investigator for its KATELYN-ERIN clinical trial. The study will evaluate genTRU-breast™, Mammogen's RNA-powered blood-based assay being developed to support earlier breast cancer detection, particularly for women with dense breast tissue. Dr. Kaltman brings 20 years of experience in oncology, cancer prevention, and clinical research. Her leadership marks an important step as Mammogen advances its clinical validation efforts and explores how blood-based diagnostics can complement traditional breast imaging. Click Here to Read the Full Press Release →